Fake COVID-19 vaccinations in Africa

Please use this identifier to cite or link to this item: https://essuir.sumdu.edu.ua/handle/123456789/87786

Or use following links to share this resource in social networks: Recommend this item

Title	Fake COVID-19 vaccinations in Africa
Authors	Aborode, A.T. Awuah, W.A. Talukder, S. Oyeyemi, A.A. Nansubuga, E.P. Machai, P. Tillewein, H. Oko, C.I.
ORCID
Keywords	COVID-19 COVAX programme Africa
Type	Article
Date of Issue	2022
URI	https://essuir.sumdu.edu.ua/handle/123456789/87786
Publisher	BMJ
License	Creative Commons Attribution - NonCommercial 4.0 International
Citation	Aborode AT, Awuah WA, Talukder S, et al. Fake COVID-19 vaccinations in Africa. Postgraduate Medical Journal 2022;98:317-318.
Abstract	Deliveries of vaccine supplies by the COVAX programme under the WHO commenced in February 2021.1 COVAX has proposed to distribute 520 million doses to Africa by the end of 2021.1 On 28 March 2021, African Union member states endorsed purchasing 220 million doses of the Johnson & Johnson single shot of the COVID-19 vaccine. However, priority was given to the Johnson & Johnson vaccine to the central-most pooled procurement due to being a single-shot vaccine, being cheap and easy to administer, having good storage conditions and production of doses being within Africa, with fill–finish activities taking place in South Africa.
Appears in Collections:	Наукові видання (НН МІ)